Alnylam Pharmaceuticals
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Alnylam Pharmaceuticals
- Company name
- Alnylam Pharmaceuticals
- Organisation type
- Industry
- Registered legal name
- Alnylam Pharmaceuticals, Inc.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- Website
- http://www.alnylam.com/
- SEC filer number (CIK)
- 0001178670
- Legal Entity Identifier (LEI)
- 529900S3ZI14OWRJII50
- Wikidata ID
- Q16974682
Related records
Trials (95)
- A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
- A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
- A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
- A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
- A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers
- A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
- A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
- A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
- A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
- A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
- A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
- A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
- A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
- A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
- A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
- A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
- A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers
- A Study to Evaluate ALN-2232 in Participants With Obesity
- A Study to Evaluate ALN-4285 in Adult Healthy Volunteers